Colorectal Cancer Articles

Tailored Approaches Offer Curative Potential to CRC Subsets
Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.
Targeted Treatments Usher in Individualized Care in mCRC
Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.
Molecular Markers Gaining Greater Influence in CRC Paradigm
Mohamed E. Salem, MD, highlights ongoing research efforts to potentially improve survival in patients with metastatic colorectal cancer.
Testing, Treatment Options Added to NCCN CRC Guidelines
A theme of the 2019 NCCN Annual Conference was the expansion of biomarker testing to guide treatment, and a review of brand-new changes for guidelines in colorectal cancer was no different.
Key Trials Seek to Expand on Efficacy, Tolerability of Treatment Regimens in Refractory CRC
Iman Imanirad, MD, discusses these trials in depth and their impact on patients with refractory metastatic colorectal cancer.
GI Oncologist Sheds Light on Present and Future of mCRC Treatment
Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.
Encorafenib/Binimetinib-based Triplet Added to NCCN Guidelines for BRAF+ CRC
The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.
Expert Highlights Evidence-Based Decision-Making in mCRC
Michael S. Lee, MD, sheds light on the treatment options available in the metastatic colorectal cancer space and highlights strategies poised to improve patient outcomes.
Strickler Stresses Continued Focus on Molecular Subtypes in mCRC
John Strickler, MD, highlights important data in the metastatic colorectal cancer space and challenges that remain for oncologists working in the field.
Management of Metastatic CRC Rooted in Molecular Subsets
John L. Marshall, MD, discusses the current and future scope of metastatic colorectal cancer.
Publication Bottom Border
Border Publication